Anti-CYP4V2 monoclonal antibody
Pre-made anti-CYP4V2 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to CYP4V2/CYP4V2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP0658-Ab-1/ GM-Tg-hg-IP0658-Ab-2 | Anti-Human CYP4V2 monoclonal antibody | Human |
GM-Tg-rg-IP0658-Ab-1/ GM-Tg-rg-IP0658-Ab-2 | Anti-Rat CYP4V2 monoclonal antibody | Rat |
GM-Tg-mg-IP0658-Ab-1/ GM-Tg-mg-IP0658-Ab-2 | Anti-Mouse CYP4V2 monoclonal antibody | Mouse |
GM-Tg-cynog-IP0658-Ab-1/ GM-Tg-cynog-IP0658-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CYP4V2 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP0658-Ab-1/ GM-Tg-felg-IP0658-Ab-2 | Anti-Feline CYP4V2 monoclonal antibody | Feline |
GM-Tg-cang-IP0658-Ab-1/ GM-Tg-cang-IP0658-Ab-2 | Anti-Canine CYP4V2 monoclonal antibody | Canine |
GM-Tg-bovg-IP0658-Ab-1/ GM-Tg-bovg-IP0658-Ab-2 | Anti-Bovine CYP4V2 monoclonal antibody | Bovine |
GM-Tg-equg-IP0658-Ab-1/ GM-Tg-equg-IP0658-Ab-2 | Anti-Equine CYP4V2 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP0658-Ab-1/ GM-Tg-hg-IP0658-Ab-2; GM-Tg-rg-IP0658-Ab-1/ GM-Tg-rg-IP0658-Ab-2; GM-Tg-mg-IP0658-Ab-1/ GM-Tg-mg-IP0658-Ab-2; GM-Tg-cynog-IP0658-Ab-1/ GM-Tg-cynog-IP0658-Ab-2; GM-Tg-felg-IP0658-Ab-1/ GM-Tg-felg-IP0658-Ab-2; GM-Tg-cang-IP0658-Ab-1/ GM-Tg-cang-IP0658-Ab-2; GM-Tg-bovg-IP0658-Ab-1/ GM-Tg-bovg-IP0658-Ab-2; GM-Tg-equg-IP0658-Ab-1/ GM-Tg-equg-IP0658-Ab-2 |
Products Name | Anti-CYP4V2 monoclonal antibody |
Format | mab |
Target Name | CYP4V2 |
Protein Sub-location | Introcelluar Protein |
Category of antibody | |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-CYP4V2 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP0658-Ag-1 | Recombinant multi-species CP4V2/ CYP4V2/ BCD protein |
Target information
Target ID | GM-IP0658 |
Target Name | CYP4V2 |
Gene ID | 285440,102294,266761,696520,102152484,101097556,510156,100056687 |
Gene Symbol and Synonyms | BCD,CYP4AH1,CYP4V2,Cyp4v3 |
Uniprot Accession | Q6ZWL3,A2RRT9 |
Uniprot Entry Name | CP4V2_HUMAN,CP4V2_RAT |
Protein Sub-location | Introcelluar Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000145476 |
Target Classification | N/A |
The target: CYP4V2, gene name: CYP4V2, also named as BCD, CYP4AH1. This gene encodes a member of the cytochrome P450 hemethiolate protein superfamily which are involved in oxidizing various substrates in the metabolic pathway. It is implicated in the metabolism of fatty acid precursors into n-3 polyunsaturated fatty acids. Mutations in this gene result in Bietti crystalline corneoretinal dystrophy. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.